Galapagos reported EUR3.82B in Assets for its fiscal quarter ending in June of 2025.


Assets Change Date
argenx SE 7.18B 973.07M Jun/2025
AstraZeneca USD 112.42B 6.17B Jun/2025
Biogen USD 28.33B 297.1M Jun/2025
Genmab DKK 6.46B 122M Jun/2025
Gilead Sciences USD 55.72B 713M Jun/2025
GlaxoSmithKline GBP 59.26B 1.45B Jun/2025
GRIFOLS EUR 19.77B 1.21B Jun/2025
Hikma Pharmaceutical USD 5.13B 286M Dec/2024
Incyte USD 5.82B 71.99M Jun/2025
Merck EUR 47.35B 2.02B Jun/2025
Neurocrine Biosciences USD 3.89B 202.1M Jun/2025
Novartis USD 104.4B 4.45B Jun/2025
Roche Holding CHF 101.8B 6.02B Dec/2024
Sanofi 124.96B 6.93B Jun/2025
UCB EUR 17.35B 1.72B Dec/2024
Vertex Pharmaceuticals USD 24.04B 1.16B Jun/2025